William N. Hait
Research Subjects
Research Interests
William N. Hait has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Jin-Ming Yang
Department of Pharmacology, The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center, Hershey, PA 17033, USA
7 shared publications Elizabeth Alli
2 shared publicationsJudy Bash-Babula
2 shared publicationsWeichung Shih
2 shared publicationsArnold J. Levine
Institute for Advanced Studies, Princeton, New Jersey and The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
1 shared publication- David Allen August
Switzerland
1 shared publication
Latest Publications
- 16 June 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (6) , 1013-1015
Thinking about a move from academia to industry? Look before you leap
- 16 June 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (6) , 1013-1015
Thinking about a move from academia to industry? Look before you leap
- Open Access
- 26 March 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 43 (9) , 2090-2092
Academic entrepreneurship: promise and perils
- 26 March 2025
- Published by Elsevier in Trends in Biotechnology
- Vol. 43 (9) , 2090-2092
Open AccessAcademic entrepreneurship: promise and perils
- 15 November 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (22) , 5587-5588
Joseph R. Bertino: In Memoriam (1930–2021)
Few individuals define the physician scientist as well as Joseph R. Bertino, MD, FAACR, who died October 11 surrounded by family and friends. He was 91.
- 15 November 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (22) , 5587-5588
Joseph R. Bertino: In Memoriam (1930–2021)
Few individuals define the physician scientist as well as Joseph R. Bertino, MD, FAACR, who died October 11 surrounded by family and friends. He was 91.
- Open Access
- 1 October 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-4
A primer for academic entrepreneurs on academic-industrial partnerships
Partnerships between academic investigators and industry can accelerate the translation of research findings into life-saving products. The healthcare industry has witnessed heightened interest from universities in capitalizing on the discoveries made by faculty to create intellectual property, form new companies and seek investments. However, academic investigators and even Biotechnology start-ups may be unfamiliar with how industry sources and evaluates these opportunities. In this Comment, we share the approaches and principles by which a large healthcare company sources innovation and assesses opportunities to serve as a guide to better deal making with the goal of improving health for humanity.
- 1 October 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-4
Open AccessA primer for academic entrepreneurs on academic-industrial partnerships
Partnerships between academic investigators and industry can accelerate the translation of research findings into life-saving products. The healthcare industry has witnessed heightened interest from universities in capitalizing on the discoveries made by faculty to create intellectual property, form new companies and seek investments. However, academic investigators and even Biotechnology start-ups may be unfamiliar with how industry sources and evaluates these opportunities. In this Comment, we share the approaches and principles by which a large healthcare company sources innovation and assesses opportunities to serve as a guide to better deal making with the goal of improving health for humanity.
- Open Access
- 31 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 9 (8) , 635-637
Disease Interception: Myths, Mountains, and Mole Hills
Malignant diseases develop slowly over time and are often preceded by identifiable premalignancies. As malignancy progresses, so does genomic complexity and the ability of cancers to evade most therapeutic interventions. Accordingly, with some notable exceptions, a relatively low percentage of advanced cancers are effectively treated and even fewer are cured. Despite this appreciation, much less attention has been paid to intercepting the disease process compared with that of treating well-established and refractory disease. One frequently cited reason is that the pharmaceutical industry is not interested in these pursuits. In this commentary, we attempt to define the true hurdles, the degree of difficulty inherent in each, and some important approaches to be considered. Cancer Prev Res; 9(8); 635–7. ©2016 AACR.
- 31 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 9 (8) , 635-637
Open AccessDisease Interception: Myths, Mountains, and Mole Hills
Malignant diseases develop slowly over time and are often preceded by identifiable premalignancies. As malignancy progresses, so does genomic complexity and the ability of cancers to evade most therapeutic interventions. Accordingly, with some notable exceptions, a relatively low percentage of advanced cancers are effectively treated and even fewer are cured. Despite this appreciation, much less attention has been paid to intercepting the disease process compared with that of treating well-established and refractory disease. One frequently cited reason is that the pharmaceutical industry is not interested in these pursuits. In this commentary, we attempt to define the true hurdles, the degree of difficulty inherent in each, and some important approaches to be considered. Cancer Prev Res; 9(8); 635–7. ©2016 AACR.
- 24 September 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 6 (255) , 255cm10
Genomic Complexity: A Call to Action
Because of their genomic simplicity relative to mature cancers, pre-malignant tissues might harbor therapeutic targets for drugs that destroy cancers before they appear.
- 24 September 2014
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 6 (255) , 255cm10
Genomic Complexity: A Call to Action
Because of their genomic simplicity relative to mature cancers, pre-malignant tissues might harbor therapeutic targets for drugs that destroy cancers before they appear.
- 1 June 2014
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 4 (6) , 646-649
Surviving Metabolic Stress: Of Mice (Squirrels) and Men
Summary: Understanding how cancer cells survive harsh environmental conditions may be fundamental to eradicating malignancies proven to be impervious to treatment. Nutrient and growth factor deprivation, hypoxia, and low pH create metabolic demands that require cellular adaptations to sustain energy levels. Protein synthesis is one of the most notable consumers of energy. Mounting evidence implicates exquisite control of protein synthesis as a survival mechanism for both normal and malignant cells. In this commentary, we discuss the role of protein synthesis in energy conservation in cancer and focus on elongation factor-2 kinase, a downstream component of the PI3K–AKT pathway that behaves as a critical checkpoint in energy consumption. Cancer Discov; 4(6); 646–9. ©2014 AACR.
- 1 June 2014
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 4 (6) , 646-649
Surviving Metabolic Stress: Of Mice (Squirrels) and Men
Summary: Understanding how cancer cells survive harsh environmental conditions may be fundamental to eradicating malignancies proven to be impervious to treatment. Nutrient and growth factor deprivation, hypoxia, and low pH create metabolic demands that require cellular adaptations to sustain energy levels. Protein synthesis is one of the most notable consumers of energy. Mounting evidence implicates exquisite control of protein synthesis as a survival mechanism for both normal and malignant cells. In this commentary, we discuss the role of protein synthesis in energy conservation in cancer and focus on elongation factor-2 kinase, a downstream component of the PI3K–AKT pathway that behaves as a critical checkpoint in energy consumption. Cancer Discov; 4(6); 646–9. ©2014 AACR.
- Open Access
- 1 October 2011
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (5) , 383-390
Forty Years of Translational Cancer Research
Forty years after the signing of the National Cancer Act, we have produced a stunning repository of scientific information that is being translated into better therapies for patients. Although challenges remain, many solutions have been adopted, leading to early signs of progress against some of humankind's most dreadful diseases. This Prospective attempts to highlight some of the approaches that have been successful and analyze some that have not, and peers into a future in which renewal of the investment in cancer research will produce further benefits for patients. Cancer Discovery; 1(5): 383–90. ©2011 AACR.
- 1 October 2011
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (5) , 383-390
Open AccessForty Years of Translational Cancer Research
Forty years after the signing of the National Cancer Act, we have produced a stunning repository of scientific information that is being translated into better therapies for patients. Although challenges remain, many solutions have been adopted, leading to early signs of progress against some of humankind's most dreadful diseases. This Prospective attempts to highlight some of the approaches that have been successful and analyze some that have not, and peers into a future in which renewal of the investment in cancer research will produce further benefits for patients. Cancer Discovery; 1(5): 383–90. ©2011 AACR.
- 1 April 2010
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (4) , 253-254
Anticancer drug development: the grand challenges
Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?
- 1 April 2010
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (4) , 253-254
Anticancer drug development: the grand challenges
Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?
- 12 February 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (4) , 1263-1267
Targeted Cancer Therapeutics
Targeted therapies can be defined as drugs developed against a specific target based on its important biological function in cancer. In contrast, nontargeted therapies are drugs identified by phenotypic screening of natural products or chemical libraries against established cancer cell lines or preclinical animal models without a priori knowledge of the target. Targeted therapies are designed to selectively inhibit a target that is abnormal in malignant compared with normal tissues; these drugs often affect proximal events in signaling pathways that drive abnormal growth and have relatively low toxicity. In contrast, nontargeted therapies affect proteins or nucleic acids that may or may not be abnormal in malignant compared with normal tissues; these drugs often target the downstream consequences of activated signaling pathways, e.g., DNA synthesis and microtubule assembly, and are toxic. Whereas targeted therapies are highly effective in selected hematopoietic malignancies, most have shown limited efficacy against complex solid tumors. In contrast, nontargeted drugs include some of the most effective yet most toxic drugs in the oncology pharmacopoeia. In the future, advances in genomics, proteomics, biology, biomarkers, chemistry, and protein engineering will coalesce to accelerate the development of increasingly selective and effective targeted therapies. Understanding the target in context will help identify biomarkers predictive of response. Finally, a detailed understanding of the target's structure and function will help anticipate and identify mechanism of drug resistance and help design drugs and combinations of drugs that retain activity. [Cancer Res 2009;69(4):1263–7]
- 12 February 2009
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (4) , 1263-1267
Targeted Cancer Therapeutics
Targeted therapies can be defined as drugs developed against a specific target based on its important biological function in cancer. In contrast, nontargeted therapies are drugs identified by phenotypic screening of natural products or chemical libraries against established cancer cell lines or preclinical animal models without a priori knowledge of the target. Targeted therapies are designed to selectively inhibit a target that is abnormal in malignant compared with normal tissues; these drugs often affect proximal events in signaling pathways that drive abnormal growth and have relatively low toxicity. In contrast, nontargeted therapies affect proteins or nucleic acids that may or may not be abnormal in malignant compared with normal tissues; these drugs often target the downstream consequences of activated signaling pathways, e.g., DNA synthesis and microtubule assembly, and are toxic. Whereas targeted therapies are highly effective in selected hematopoietic malignancies, most have shown limited efficacy against complex solid tumors. In contrast, nontargeted drugs include some of the most effective yet most toxic drugs in the oncology pharmacopoeia. In the future, advances in genomics, proteomics, biology, biomarkers, chemistry, and protein engineering will coalesce to accelerate the development of increasingly selective and effective targeted therapies. Understanding the target in context will help identify biomarkers predictive of response. Finally, a detailed understanding of the target's structure and function will help anticipate and identify mechanism of drug resistance and help design drugs and combinations of drugs that retain activity. [Cancer Res 2009;69(4):1263–7]